StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
301617.SZ$53.00+1.92%
Fair $53.00+0.0%

301617.SZ

Shandong Boyuan Pharmaceutical & Chemical Co., Ltd.

Basic Materials / ChemicalsShenzhen

$53.00

+1.00 (+1.92%)

Fairly Valued+0.0%Fair Value $53.00Fund rank 29/100 · Data gapFallback financials|
SA 55/C
F-Score: 2/9
Margin Compression

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 23%

FCF escenarios

weak_data · normalized FCF $79.3M · quality 49.0/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 30/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

55/100

C

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Operating margin has declined for 3 consecutive years
Thesis & Journal · 301617.SZLocal privado en este navegador · Shandong Boyuan Pharmaceutical & Chemical Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9.2B

P/E

53.0x

↑

EV/EBITDA

29.2x

↑

ROE

10.0%

↑

Gross Margin

20.2%

↓

Debt/Equity

0.00

↓
52-Week Range$53
$27$85

TradingView lightweight chart

301617.SZ price, volumen y niveles de valoración

Último $52.00Periodo +9.7%
Fair value: $53.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+22.4%

FCF CAGR

—

FCF margin

-6.0%

FCF / Net income

-0.51x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.46B · net income $172.3M · FCF $-88.1M

2022-FY → 2025-FY

Gross margin

20.2%-79.8% pts

Operating margin

13.6%-86.4% pts

Net margin

11.8%-10.3% pts

FCF margin

-6.0%-29.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.46B$1.46B$1.33B$1.03B$798.5M
Net Income$172.3M$172.3M$212.8M$182.1M$176.3M
EBITDA$230.8M$230.8M$273.7M$233.0M$219.2M
EPS1.291.292.122.361.76
Gross Margin20.2%20.2%24.8%27.9%100.0%
Operating Margin13.6%13.6%18.6%20.8%100.0%
Net Margin11.8%11.8%16.0%17.8%22.1%
Balance Sheet
Debt/Equity0.000.000.000.00—
Current Ratio7.077.07———
Cash Flow
Free Cash Flow$-88.1M$-88.1M$106.3M$79.3M$189.0M
Returns
ROE10.0%10.0%12.8%22.5%—
Valuation
P/E53.0053.0013.12——
EV/EBITDA29.1829.186.70——
P/B4.094.091.68——
Growth & Yield
Revenue Growth10.3%10.3%29.5%28.4%—
EPS Growth-39.2%-39.2%-10.2%34.2%—
Dividend Yield0.7%0.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

53.9%

muy exigente

EPS terminal req.

$4.70

Spread vs growth

-93.1%

5Y implied EPS CAGR

34.6%

muy exigente

EPS terminal req.

$5.69

Spread vs growth

-73.7%

10Y implied EPS CAGR

21.7%

exigente

EPS terminal req.

$9.16

Spread vs growth

-60.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +87.2%

Total return

+87.2%

Start / end P/E

13.4x → 41.1x

EPS bridge

2.12 → 1.29

Residual

-80.9%

EPS growth-39.2%
Multiple rerating+206.6%
Dividend+0.7%
Residual / FX / buybacks / cross-term-80.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.